Top 5 Drug Type | Count |
---|---|
Oncolytic virus | 2 |
Monoclonal antibody | 1 |
Prophylactic vaccine | 1 |
Target |
Mechanism PD-1 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date28 Sep 2018 |
Target |
Mechanism IFNβ stimulants [+3] |
Active Org. Vyriad, Inc.Startup |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism NIS modulators [+1] |
Active Org. Vyriad, Inc.Startup |
Originator Org. Vyriad, Inc.Startup |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Apr 2020 |
Sponsor / Collaborator Vyriad, Inc.Startup [+1] |
Start Date09 Apr 2019 |
Sponsor / Collaborator Vyriad, Inc.Startup [+1] |
Start Date20 Jul 2018 |
Sponsor / Collaborator Vyriad, Inc.Startup [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Cemiplimab-RWLC ( PD-1 ) | Squamous Cell Carcinoma of Head and Neck More | Phase 2 |
VSV-IFNbeta-NIS ( IFNβ x NIS ) | Colorectal Cancer More | Phase 2 |
Oncolytic measles virus encoding thyroidal sodium iodide symporter(Vyriad, Inc.) ( NIS ) | Peritoneal Neoplasms More | Phase 2 |
VSV-SARS2(+G) ( SARS-CoV-2 S protein ) | Coronavirus Infections More | Preclinical |
COVID-2019 vaccine(Vyriad) ( SARS-CoV-2 S protein ) | COVID-19 More | Discontinued |